We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Pharmatek Announces Acquisition of Additional Xcelodose® 600S System
News

Pharmatek Announces Acquisition of Additional Xcelodose® 600S System

Pharmatek Announces Acquisition of Additional Xcelodose® 600S System
News

Pharmatek Announces Acquisition of Additional Xcelodose® 600S System

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Pharmatek Announces Acquisition of Additional Xcelodose® 600S System"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Pharmatek has announced that it has purchased another Xcelodose® 600S system.

This acquisition doubles the company's manufacturing production rate for powder-in-capsule (PIC) operations and increases overall preclinical and early phase clinical cGMP supply capabilities.

"The acquisition of an additional Xcelodose® unit enables Pharmatek to better serve our clients' early phase development strategies and meet the growing demand for PIC projects," stated Kevin Rosenthal, Director of Manufacturing at Pharmatek.

Rosenthal continued, "For PIC applications, the Xcelodose® can drastically decrease time to clinic while also lowering the cost of drug product for first-in-human trials."

In addition to adding another Xcelodose® system, Pharmatek has implemented a dedicated Xcelodose® project team to ensure the overall success and quick turnaround of PIC programs.

Each team is led by an Xcelodose® engineer who oversees the project from planning to execution.

The Xcelodose®, manufactured by Capsugel, is a precision powder micro-doser and automated encapsulator that has the ability to fill formulations or active pharmaceutical ingredient (API) directly into capsules with a remarkable level of accuracy.

The Xcelodose® can measure to levels as low as 100 micrograms and can dispense into capsules from size 00 to 4. Dosing directly into capsules can reduce the amount of API required.

Additionally, the unit minimizes overall development time by simplifying analytical and stability protocols.

Advertisement